Answers are grounded in this paper and cite their sources.
Summary Management of B‐cell acute lymphoblastic leukaemia (B‐ALL) in patients with Down syndrome (DS‐ALL) is complicated by increased toxicity and relapse rates. For first relapse of DS‐ALL, optimal management is uncertain. Chimeric antigen receptor T‐cell (CAR‐T) therapy offers an alternate approach for remission induction and/or definitive curative therapy, and recent reports suggest similar efficacy and tolerability in DS and non‐DS patients. We distributed an international survey to paediatric oncologists treating DS‐ALL querying opinions on therapy, monitoring and toxicity in this population. Among 89 respondents, 76%, 80% and 64% favoured definitive CAR‐T therapy without intent for subsequent haematopoietic stem cell transplantation (HSCT) for early medullary relapse, early and late isolated extra‐medullary relapse respectively. For late medullary relapse, 47% preferred definitive CAR‐T whereas 51% chose definitive chemoimmunotherapy. Only a minority of respondents selected HSCT as a planned approach for any first relapse: 11%–15% for early relapse; 3%–5% for late relapse. The main perceived benefit of CAR‐T therapy was its favourable toxicity profile. Overall, 56% and 77% of respondents felt that it should be considered standard of care for low and high‐risk relapse of DS‐ALL respectively. Survey responses suggest that developing guidelines to integrate use of CAR‐T is warranted for first relapse in DS‐ALL.
No takes yet. Share an insight, caveat, or question.
Rubinstein et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: